Результаты поиска

The 48th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians - Oral Sessions (O009-O155).

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Tumor Biology Hides Novel Therapeutic Approaches to Diffuse Large B-Cell Lymphoma: A Narrative Review.

Diffuse large B-cell lymphoma (DLBCL) is a malignancy of immense biological and clinical heterogeneity. Based on the transcriptomic or genomic approach, several different classification schemes have evolved over the years to subdivide DLBCL into clinically (prognostically) relevant subsets, but each leaves unclassified samples. Herein, we outline the DLBCL tumor biology behind the actual and potential drug targets and address the challenges and drawbacks coupled with their (potential) use. Therapeutic modalities are discussed, including small-molecule inhibitors, naked antibodies, antibody-dru

NAPCON 2025 – Best Original Research Abstracts

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… Kuttanad, Kerala’s “Rice Bowl,” lies below sea level with recurrent floods, humidity, saline intrusion, and pesticide use. These unique exposures may worsen asthma, yet control and lung function in this region remain under studied. …

Hematopoietic Tumors

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

:: 45th Ежегодное совещание Европейского общества по трансплантации крови и костного мозга: Врачи - сессия плаката.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Esid 2014 oral presentations.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

СНМИКОН 2024 Резюме

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

9th Trends in Medical Mycology Held on 11-14 October 2019, Nice, France, Organized under the Auspices of EORTC-IDG and ECMM.

Dear Friends and Colleagues,It is a great honor and pleasure for us to invite you cordially to participate in the 9th Congress on Trends in Medical Mycology (TIMM-9) [...].

Tumor biomarkers for diagnosis, prognosis and targeted therapy.

Tumor biomarkers, the substances which are produced by tumors or the body's responses to tumors during tumorigenesis and progression, have been demonstrated to possess critical and encouraging value in screening and early diagnosis, prognosis prediction, recurrence detection, and therapeutic efficacy monitoring of cancers. Over the past decades, continuous progress has been made in exploring and discovering novel, sensitive, specific, and accurate tumor biomarkers, which has significantly promoted personalized medicine and improved the outcomes of cancer patients, especially advances in molecu

Abstracts

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Navigating the landscape of protein folding and proteostasis: from molecular chaperones to therapeutic innovations.

Protein folding is a fundamental process ensuring that polypeptide chains acquire the correct three-dimensional structures required for biological function. This complex journey from nascent polypeptides to mature proteins is tightly regulated by the cellular proteostasis network-an integrated system of molecular chaperones, folding enzymes, and degradation machineries. Disruptions in this network lead to dysproteostasis, a pathological state implicated in a growing list of human diseases, including neurodegenerative disorders, metabolic syndromes, and cancer. In this review, we provide a comp

Hematopoietic Tumors

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

The 44th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians Oral Session

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

The 46th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians Poster Session (P001-P706).

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018) : Washington, D.C., USA. 7-11 November 2018.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Integumentary System

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges.

Ubiquitin Proteasome System (UPS) is an adaptable and finely tuned system that sustains proteostasis network under a large variety of physiopathological conditions. Its dysregulation is often associated with the onset and progression of human diseases; hence, UPS modulation has emerged as a promising new avenue for the development of treatments of several relevant pathologies, such as cancer and neurodegeneration. The clinical interest in proteasome inhibition has considerably increased after the FDA approval in 2003 of bortezomib for relapsed/refractory multiple myeloma, which is now used in

34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019): part 2 : National Harbor, MD, USA. 10 November 2019.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Rapid Fire

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

C

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.